Results
415 adult patients, mean age 36.6 years, 61.4% female, 36% asthmatic were included. 65.3% of patients experienced possibly-related adverse events (AEs). These mostly mild (67%) AEs comprised: oral allergic reactions (58.6%), respiratory (12.4%) and gastrointestinal symptoms (9.4%).
60 (14.5%) patients stopped due to AEs and 76 (18.3%) for non-AE reasons. Mean CARAT scores improved clinically significant by 6 points and symptomatic medication use decreased from 96.1% to 77.4%. 74.5% of patients tolerated the treatment well. Most patients were compliant (>86.5%) and patients (62.4 %) and investigators (69.4%) were satisfied with treatment.